Guardant Health heads into its May 7 Q1 2026 earnings print with options positioning flashing the most bullish signal in months — a sharp contrast to how the stock was positioned just two weeks ago.
The options market tells a striking story. The put/call ratio has collapsed to 0.59, more than two standard deviations below its 20-day mean of 1.05. That's the lowest reading since the start of the year and close to the 52-week floor of 0.43. As recently as mid-April, the PCR was running above 1.36 — well into defensive territory. The pivot over just the last week of April is abrupt, and it coincides almost exactly with the stock's recovery: shares closed at $91.17 on May 4, up 4% on the day and 3% on the week, after a rough month that still leaves the stock down roughly 3% from a month ago.
Short sellers have been moving in the same direction. Nearly 2.5 million shares of short interest were covered in just a few days around April 23-24, pulling SI from above 14.7 million shares to around 12.3 million — a drop of 16% in a week. At 9.5% of the free float, GH is not lightly shorted, but the direction of travel is clear. The borrow market is relaxed: cost to borrow is a negligible 0.41% annualised, and availability is loose, meaning the lending pool is not under meaningful strain. Short score, which peaked near 59 on April 22, has eased to just under 55. The combination of short covering and a call-heavy options tilt suggests the investor base is repositioning for a positive outcome from the print.
The debate is real, though. Bulls point to Guardant's commanding position in liquid biopsy — over 50% share in circulating genomic profiling — and nearly 30% year-on-year volume growth. The company has consistently beaten estimates, ranking in the 93rd percentile for EPS surprise. Sixteen analysts carry a buy recommendation, and consensus analyst upside from current levels is a substantial 46.5%. The more cautious case centers on reimbursement risk: potential PAMA regulation changes could trigger a one-time revenue hit of roughly $100 million, and uncertainty around multi-cancer early detection reimbursement may cap ASP growth. Recent analyst activity reflected that tension — Barclays trimmed its target from $130 to $115 in mid-April while keeping Overweight, and Evercore ISI cut from $110 to $90 in early April while staying neutral. Analyst targets now span a wide range, and the post-February rally that prompted multiple upgrades has given way to more selective trimming.
Institutional ownership adds one more thread. T. Rowe Price added over 1.4 million shares in Q1, a notable increase that brings its stake to 4.3% of the company. Co-founders AmirAli Talasaz (CEO) and Helmy Eltoukhy both added incrementally in late April — modest in size but directionally aligned with the bullish options shift. The May 7 print will test whether the company's revenue trajectory and ASP outlook can justify the re-rating that options and short-side flows have already begun to price in.
See the live data behind this article on ORTEX.
Open GH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
